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Poster Session-I 63p 5 0.27). Cause of death was relapse 23%, aGVHD 2%, cGVHD
1%, infection 2%, MSOF/ ARDS 3% and other 2%. In conclusion:
the use of t-Bu/Flu in AML patients, with a daily AUC targeted at
5300610% is a tolerable regimen with lowNRM. It is also well tol-
erated regardless of age. Patients in a first CR, even those with URC,
have very good outcomes. Relapse is still an issue in these AML pa-
tients and post transplant therapy should be considered, particularly
for patients not in remission at the time of transplant. Currently we
are assessing the maximum tolerated AUC of Bu in an ongoing trial.168
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Champlin, R.E., de Lima, M., Giralt, S., Kebriaei, P., Anderlini, P.,
Qazilbash, M., Hosing, C., Shpall, E., Fisher, T., Gabriela, R. MD An-
derson Cancer Center, Houston, TX
Allogeneic stem cell transplantation (ASCT) is a potentially cura-
tive therapy for patients(pts) with CML. Its use has declined because
of the favorable results of tyrosine kinase inhibitors (TKIs), and con-
cerns regarding toxicity andGVHD.The efficacy of ASCT is largely
due to the immune graft-vs.-leukemia effect. Nonmyeloablative con-
ditioning has reduced toxicity, and post transplant treatment with
imatinib and donor lymphocyte infusions can produce durable mo-
lecular complete remissions in pts with residual disease.We prospec-
tively studied use of a reduced intensity preparative regimen
involving fludarabine, busulfan and Thymoglobulin followed by
ASCT from an HLA identical or one antigen mismatched related
or unrelated donor. Pts who do not achieve molecular CR (mCR) af-
ter 3 mo received TKI treatment. Those without mCR after an ad-
ditional 3 mo received escalating doses of donor lymphocyte
infusion (DLI). 42 pts, median age 42 yrs (range 14–69) were en-
tered. All were previously treated with imatinib, but with detectable
disease. 20 had early disease (chronic phase or isolated clonal evolu-
tion) and 22 had advanced CML (prior accelerated or blast phase). 4
early and 9 advanced pts had a cytogenetic CR (CyCR) at the time of
transplant. The regimen was well tolerated without life-threatening
toxicity except for one pt with reversible transplant related microan-
gioapathy. Two pts had graft failure, one required a second trans-
plant and the other had autologous recovery with Ph-
hematopoiesis. Only one pt died within 100 days post transplant.
At 3 months, all of the chronic phase pts and 21 of the 18 advanced
pts achieved CyCR and 7 early and 5 advanced pts achieved a mCR.
22 pts received treatment with TKIs post transplant; mCR was
achieved in 7 of the 9 early pts and 2 of 13 advanced pts. 16 pts sub-
sequently received DLI; 2 of 2 pts with early disease achieved mCR
with one other pt too early to evaluate; 2 of 13 advanced pts have
a mCR. 31 pts are alive. This includes 18 of 20 (90%) transplanted
with early disease, (all in cCyR 13 in cMR) and 13 of the 22 (59%)
with advanced disease (7 in cCyR and 9 in cMR). This sequential
strategy of nonmyeloablative ASCT, post transplant TKIs, and
DLI is associated with a low treatment relatedmortality and deserves
further study to produce durable mCR in patients with a suboptimal
response to imatinib. Most favorable results were achieved in pts
without overt transformation.169
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Background:RIC regimens are less myelosuppressive, but still al-
low for successful engraftment with acceptable treatment-related
mortality (TRM) in frail pts who otherwise would not be suitable
candidates for HSCT. This is particularly relevant in ALL, since
pts often sustain toxicity from dose-intense regimens, or may bediagnosed in advanced age. The antitumor effect of this approach
is not well-established in ALL.
Methods: We evaluated 30 ALL pts (19 M/11 F) treated from
1996 to 2008 with fludarabine 120 mg/m2, melphalan 140 mg/m2
and unmanipulated stem cells. GVHD prophylaxis consisted of
tacrolimus and mini-methotrexate. Anti-thymocyte-globulin was
added to matched unrelated pts.
Results: Median age was 44 years (range 23–64). ECOG status at
time of HSCT was 0 (n 5 16), 1 (n 5 10) or 2 (n 5 4) with median
co-morbidity score of 3 (range 0–7) by Charlson Comorbidity Index.
24 pts had B-lineage and 6 had T-lineage disease. Cytogenetic data
were available for 26 pts; 19 had high-risk cytogenetics, including
9 with Ph1 disease. Disease stage at time of study entry was CR1
(n 5 5), $CR1 (n 5 12), or primary or refractory relapse (n 5 13),
with median 2 prior chemotherapy regimens (range 1–4); five pts
had a prior allogeneic HSCT. Donor type was matched related
(n 5 13) or matched unrelated (n 5 17) and stem cell source was
bone marrow (n5 14) or peripheral blood (n5 16). The median to-
tal nucleated cell dose and CD341 cell dose were 3.80  108 cells
(range 0.68 – 17.16) and 4.15 106 cells (range 1.78 – 12.03), respec-
tively. Median time to ANC 0.5  109/L was 13 days (range 10–24).
Median time to platelet count 20 109/L was 18 days (range 10–57).
Eight pts were alive at a median follow up of 12 months fromHSCT
(range 3–59). OS and DFS were 32% and 29%, respectively, at 1
year. Of note, only 1 among 5 pts in CR1 had disease progression,
compared to 8 among 13 with refractory disease at time of HSCT.
The cumulative incidence of acute GVHD, grades II-IV and III-
IV were 40% and 13%, respectively, and chronic GVHD was 22%
(7% for extensive). The cumulative incidence of TRM at 100 days
and 1 year were 17% and 33%, respectively. There were 22 deaths:
recurrence 14, infection 4, GVHD 4.
Conclusion: RIC HSCT can provide disease control in patients
with ALL, andmerits further evaluation. Alternative treatment strat-
egies need to be explored in pts with advanced disease. The observed
TRM rate is comparable to previously reported rates in in heavily
pre-treated leukemia patients.170
EPIGENETIC REGULATIONS INFLUENCE CML CELL SENSITIVITY TO
BUSULFAN: RELEVANCE TO PRETRANSPLANT CONDITIONING THERAPY
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Busulfan (Bu) is a DNA-alkylating drug which is commonly used
in myeloablative pretransplant conditioning therapy in patients with
CML. A major obstacle to successful treatment is inherent or
acquired cellular Bu-resistance. Knowing that DNA hypermethyla-
tion may contribute to drug resistance, we hypothesized that cellular
Bu-resistance can be reversed by altered epigenetic regulation. We
established a Bu-resistant CML cell line B5/Bu2506 which is 4-
fold more resistant to Bu than the parental B5 cells but 4-fold collat-
erally sensitive to 5-aza-2’-deoxycytidine (DAC). Real-time PCR
analysis of the expressions of known DNA methyltransferases
showed upregulation of DNMT3B in B5/Bu2506 cells relative to
the parental B5 cells without significant changes in DNMT1,
DNMT2, and DNMT3A. This result suggests that B5/Bu2506 cells
might be addicted to DNMT3B to epigenetically regulate expres-
sion of genes involved in Bu resistance; exposure to DAC might in-
hibit DNMT3B enzyme and sensitize cells to Bu. Indeed, exposure
to DAC synergistically increased Bu-mediated cytotoxicity in B5/
Bu2506 cells as evaluated by the MTT assay and median-effect anal-
ysis (combination index\ 0.5). The DAC-induced sensitivity to Bu
of B5/Bu2506 cells was associated with PARP1 cleavage, phosphor-
ylation of histone 2A and activation of caspases 3, 8 and 9 suggesting
induction of apoptotic response. Real-time PCR and immunostain-
ing analyses of the expressions of various viability-related genes,
which are known to be epigenetically regulated, showed significant
increase in the expression of CDKN2A (p16INK4A) and XAF1 (X-
linked inhibitor of apoptosis protein (XIAP)-associated factor 1)
genes in B5/Bu2506 cells exposed to DAC. Analyses of their
promoter regions by methylation-specific PCR showed a significant
decrease in their methylation status which correlates with the alter-
ation in their gene expression in the presence of DAC. The
